IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
IO Biotech (IOBT) presented new preclinical data for two cancer vaccine candidates at the AACR Annual Meeting 2025 in Chicago. The company showcased findings for:
1. IO102-IO103: Their lead therapeutic vaccine targeting IDO1 and PD-L1 demonstrated strong T-cell responses and unique tumor microenvironment modulation in mouse models, with effects distinct from conventional PD-1/PD-L1 inhibitors.
2. IO170: Their TGF-β-directed vaccine showed significant tumor growth inhibition in breast and prostate cancer models, increasing CD8+ T-cell density and reducing suppressive cells like M2 macrophages.
Both vaccines, developed using IO Biotech's T-win® platform, showed promising results in reshaping the tumor microenvironment to enhance anti-tumor immunity.
IO Biotech (IOBT) ha presentato nuovi dati preclinici per due candidati vaccini contro il cancro al AACR Annual Meeting 2025 di Chicago. L'azienda ha mostrato i risultati riguardanti:
1. IO102-IO103: Il loro vaccino terapeutico principale, che prende di mira IDO1 e PD-L1, ha dimostrato forti risposte delle cellule T e una modulazione unica del microambiente tumorale nei modelli murini, con effetti differenti rispetto agli inibitori convenzionali di PD-1/PD-L1.
2. IO170: Il loro vaccino diretto contro il TGF-β ha evidenziato una significativa inibizione della crescita tumorale nei modelli di cancro al seno e alla prostata, aumentando la densità di cellule T CD8+ e riducendo le cellule soppressive come i macrofagi M2.
Entrambi i vaccini, sviluppati utilizzando la piattaforma T-win® di IO Biotech, hanno mostrato risultati promettenti nel rimodellare il microambiente tumorale per potenziare l’immunità anti-tumorale.
IO Biotech (IOBT) presentó nuevos datos preclínicos para dos candidatos a vacunas contra el cáncer en la AACR Annual Meeting 2025 en Chicago. La compañía mostró hallazgos sobre:
1. IO102-IO103: Su vacuna terapéutica principal dirigida a IDO1 y PD-L1 demostró fuertes respuestas de células T y una modulación única del microambiente tumoral en modelos de ratón, con efectos distintos a los inhibidores convencionales de PD-1/PD-L1.
2. IO170: Su vacuna dirigida contra TGF-β mostró una inhibición significativa del crecimiento tumoral en modelos de cáncer de mama y próstata, aumentando la densidad de células T CD8+ y reduciendo células supresoras como los macrófagos M2.
Ambas vacunas, desarrolladas usando la plataforma T-win® de IO Biotech, mostraron resultados prometedores al remodelar el microambiente tumoral para potenciar la inmunidad antitumoral.
IO Biotech (IOBT)는 시카고에서 열린 AACR Annual Meeting 2025에서 두 가지 암 백신 후보에 대한 새로운 전임상 데이터를 발표했습니다. 회사는 다음과 같은 연구 결과를 공개했습니다:
1. IO102-IO103: IDO1과 PD-L1을 표적으로 하는 주요 치료 백신으로, 마우스 모델에서 강력한 T세포 반응과 독특한 종양 미세환경 조절을 보여주었으며, 기존 PD-1/PD-L1 억제제와는 다른 효과를 나타냈습니다.
2. IO170: TGF-β를 표적으로 하는 백신으로, 유방암 및 전립선암 모델에서 종양 성장 억제가 뚜렷하게 나타났으며, CD8+ T세포 밀도를 높이고 M2 대식세포와 같은 억제 세포를 감소시켰습니다.
두 백신 모두 IO Biotech의 T-win® 플랫폼을 활용해 개발되었으며, 종양 미세환경을 재구성하여 항종양 면역을 강화하는 데 유망한 결과를 보였습니다.
IO Biotech (IOBT) a présenté de nouvelles données précliniques pour deux candidats vaccins contre le cancer lors du AACR Annual Meeting 2025 à Chicago. La société a mis en avant les résultats concernant :
1. IO102-IO103 : Leur vaccin thérapeutique principal ciblant IDO1 et PD-L1 a démontré de fortes réponses des cellules T et une modulation unique du microenvironnement tumoral chez des modèles murins, avec des effets distincts des inhibiteurs conventionnels de PD-1/PD-L1.
2. IO170 : Leur vaccin ciblant le TGF-β a montré une inhibition significative de la croissance tumorale dans des modèles de cancer du sein et de la prostate, augmentant la densité des cellules T CD8+ et réduisant les cellules suppressives telles que les macrophages M2.
Les deux vaccins, développés grâce à la plateforme T-win® d’IO Biotech, ont montré des résultats prometteurs pour remodeler le microenvironnement tumoral afin de renforcer l’immunité antitumorale.
IO Biotech (IOBT) stellte auf dem AACR Annual Meeting 2025 in Chicago neue präklinische Daten zu zwei Krebsimpfstoffkandidaten vor. Das Unternehmen präsentierte Ergebnisse zu:
1. IO102-IO103: Ihr führender therapeutischer Impfstoff, der auf IDO1 und PD-L1 abzielt, zeigte starke T-Zell-Reaktionen und eine einzigartige Modulation des Tumormikromilieus in Mausmodellen, mit Effekten, die sich von herkömmlichen PD-1/PD-L1-Inhibitoren unterscheiden.
2. IO170: Ihr TGF-β-gerichteter Impfstoff zeigte eine signifikante Hemmung des Tumorwachstums in Brust- und Prostatakrebsmodellen, erhöhte die Dichte von CD8+ T-Zellen und reduzierte unterdrückende Zellen wie M2-Makrophagen.
Beide Impfstoffe, entwickelt mit der T-win® Plattform von IO Biotech, zeigten vielversprechende Ergebnisse bei der Umgestaltung des Tumormikromilieus zur Steigerung der antitumoralen Immunität.
- Preclinical data showed strong T-cell responses for IO102-IO103 vaccine
- IO170 demonstrated significant tumor growth inhibition in multiple cancer models
- Both vaccines successfully modulated the tumor microenvironment
- IO102-IO103 showed unique mechanism different from existing treatments
- Results are only from preclinical studies, requiring further clinical validation
- No human efficacy data presented
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine which targets cells expressing IDO1 and PD-L1, compared to conventional checkpoint inhibitors and a second shares promising updates for IO170, which targets Transforming Growth Factor beta (TGF-β).
“These data continue to strengthen our mechanistic rationale for using IO102-IO103 as a dual-antigen approach and for targeting key immunosuppressive drivers like TGF-β,” said Ayako Wakatsuki Pedersen, PhD, Senior Vice President of Translational Research at IO Biotech. “Together, these findings highlight how our vaccines act at multiple levels within the tumor microenvironment to drive more effective anti-tumor responses.”
Poster Highlights
- IO102-IO103, a dual-antigen vaccine targeting IDO1+ and PD-L1+ cells, generated strong T-cell responses and modulated the tumor microenvironment in two mouse models, where IDO1 and PD-L1 vaccine each contributed differently to control tumor growth. Gene expression profiling also showed that the vaccine triggered unique molecular changes not seen with PD-1 or PD-L1 inhibitors, indicating a potentially synergistic mechanism. (Abstract #2241)
- IO170, also developed using IO Biotech’s T-win® platform, demonstrated significant tumor growth inhibition in breast and prostate cancer mouse models. The TGF- β-directed vaccine led to infiltration of vaccine-specific T cells with increased density of CD8+ T-cells in the tumor and reshaped the tumor microenvironment to favor immune activation. Spatial analysis in prostate tumors showed increased cytotoxic immune regions and reduced levels of suppressive cells like M2 macrophages. (Abstract #2257)
The posters can be found on the “Posters & Publications” page of the IO Biotech website and, for registered participants, on the AACR website.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
What are the key findings from IO Biotech's (IOBT) cancer vaccine presentation at AACR 2025?
How does IO Biotech's IO102-IO103 cancer vaccine differ from conventional checkpoint inhibitors?
What results did IO Biotech's IO170 vaccine show in preclinical studies?
Which cancer types were tested with IO Biotech's (IOBT) IO170 vaccine in preclinical studies?
